Novo Nordisk bets on innovative insulin: "Many doctors said we were crazy"
Insulin has made its big comeback in Novo Nordisk's diabetes pipeline despite pricing pressure in the insulin market. Chief Science Officer Mads Krogsgaard Thomsen thinks the company's experimental insulins are innovative enough to make a breakthrough.
BY KEVIN GRØNNEMANN, TRANSLATED BY IDA JACOBSEN
For the first time since the insulin market stagnated due to price pressure in the US – forcing Novo Nordisk to book a notorious downgrade in 2016 – the most talked-about drug in Novo Nordisk's diabetes pipeline is once again an insulin.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
